Oncology

Mantle Cell Lymphoma

Expert Roundtables Podcast: Current Standard of Care and Recent Developments in Relapsed/Refractory Mantle Cell Lymphoma

expert roundtables by Zachary Epstein-Peterson, MD; Caron A. Jacobson, MD, MMSc; Julie M. Vose, MD, MBA, FASCO

Overview

The outcomes from relapsed/refractory mantle cell lymphoma (MCL) have improved with the emergence of treatments such as CAR T-cell therapy and BTK inhibitors. Nonetheless, there are still unmet needs in MCL, and optimal care requires considering patients’ prior therapies, disease features, preferences, and goals.

References

Jain N, Mamgain M, Chowdhury SM, et al. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol. 2023;16(1):99. doi:10.1186/s13045-023-01496-4

Romancik JT, Gerber DG, Zhuang T, Cohen JB. SOHO State of the Art Updates and Next Questions: managing relapsed mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(8):557-565. doi:10.1016/j.clml.2022.01.008

Tarockoff M, Gonzalez T, Ivanov S, Sandoval-Sus J. Mantle cell lymphoma: the role of risk-adapted therapy and treatment of relapsed disease. Curr Oncol Rep. 2022;24(10):1313-1326. doi:10.1007/s11912-022-01297-x

Thomas CJ, Carvajal V, Barta SK. Targeted therapies in the treatment of mantle cell lymphoma. Cancers (Basel). 2024;16(10):1937. doi:10.3390/cancers16101937

Wang JF, Wang Y. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Expert Rev Hematol. 2024;17(10):651-659. doi:10.1080/17474086.2024.2389993

Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42(10):1146-1157. doi:10.1200/JCO.23.02214

Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594-2606. doi:10.1200/JCO.22.01797

Wu JJ, Wade SW, Itani T, et al. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis. Leuk Lymphoma. 2024 Jul 8:1-14. doi:10.1080/10428194.2024.2369653

Profile

Zachary Epstein-Peterson, MD

Assistant Attending Physician, Lymphoma Service

Memorial Sloan Kettering Cancer Center

Instructor, Department of Medicine

Weill Cornell Medical College

New York, NY

Profile

Caron A. Jacobson, MD, MMSc

Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Profile

Julie M. Vose, MD, MBA, FASCO

George and Peggy Payne Distinguished Chair of Oncology
Chief, Oncology/Hematology
Professor of Medicine
University of Nebraska Medical Center
Omaha, NE